Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance

References

• Swerdlow SH, Campo E, Harris NL, et al. World health organization classification of tumours of haemato-poietic and lymphoid tissues. Lyon: IARC; 2017.
   Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
   Google Scholar
• Barbui T, Tefferi A, Vannucchi A, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–1069.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874–1881.
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an international prognostic score of thrombosis in world health organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128–5133.
   PubMed Web of Science ®Google Scholar
• Vannucchi A, Barbui T, Cervantes F, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v85–v99.
   PubMed Web of Science ®Google Scholar
• Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148:961–963.
   PubMed Web of Science ®Google Scholar
• Barosi G, Besses C, Birgegard G, et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia. 2007;21:277–280.
   PubMed Web of Science ®Google Scholar
• Vannucchi A, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426–435.
   PubMed Web of Science ®Google Scholar
• Demuynck T, Verhoef G, Delforge M, et al. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis. Ann Hematol. 2019;98:1421–1426.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larrán A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119:1363–1369.
   PubMed Web of Science ®Google Scholar
• Hernández-Boluda J, Alvarez-Larrán A, Gómez M, et al. Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol. 2010;152:81–88.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 world health organization–defined essential thrombocythemia at diagnosis: a study by the international working group on myelofibrosis research and treatment. Blood. 2012;120:1197–1201.
   PubMed Web of Science ®Google Scholar
• Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113:4829–4833.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larran A, Kerguelen A, Hernandez-Boluda JC, et al. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol. 2016;172:786–793.
   PubMed Web of Science ®Google Scholar
• Carobbio A, Finazzi G, Antonioli E, et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood. 2010;116:1051–1055.
   PubMed Web of Science ®Google Scholar
• Latagliata R, Spadea A, Cedrone M, et al. Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome negative myeloproliferative neoplasms: The mister Hyde face of a safe drug. Cancer. 2012;118:404–409.
   PubMed Web of Science ®Google Scholar
• Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph-negative MPN. Am J Hematol. 2012;87:552–554.
   PubMed Web of Science ®Google Scholar
• Harrison C, Campbell P, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33–45.
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood. 2013;121:1720–1728.
   PubMed Web of Science ®Google Scholar
• Palandri F, Polverelli N, Catani L, et al. Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years. Br J Haematol. 2012;156:672–686.
   PubMed Web of Science ®Google Scholar
• Kiladjian J, Zachee P, Hino M, et al. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020;7:e226–e237.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 2017;18:88–99.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Mead AJ, Panchal A, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017;130:1889–1897.
   PubMed Web of Science ®Google Scholar
• Yacoub A, Mascarenhas J, Kosiorek H, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134:1498–1509.
   PubMed Web of Science ®Google Scholar
• Ahn IE, Natelson E, Rice L. Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide. Clin Lymphoma Myeloma Leuk. 2013;13:S300–S304.
   PubMedGoogle Scholar
• Alvarez-Larrán A, Angona A, Andrade-Campos M, et al. Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish registry of essential thrombocythaemia. Br J Haematol. 2021;192:988–996.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larrán A, Díaz-González A, Such E, et al. Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea. Leukemia. 2021;35:623–627.
   PubMed Web of Science ®Google Scholar